Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Potere Health MD

Two GLP-1 desks, one scoreboard. We put Trimi and Potere Health MD head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 264 · Grade C

Potere Health MD

Visit Potere Health MD Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 64 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Potere Health MD a bad call — it's best for readers who want utah residents wanting low-cost, physician-led glp-1 weight loss without a subscription. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
89
77
Transparency
91
48
Access Breadth
89
56
Clinical Oversight
88
87
Track Record
84
82
TrimiBrief Score 89 · 64Potere Health MD

Price, coverage & the tracker

TrimiPotere Health MD
Brief Score89/100 (B+)64/100 (C)
Semaglutide$196/moFrom $80/mo (starting dose, compounded)
Tirzepatide$296/moFrom $135/mo (starting dose, compounded)
CoverageAll 50 states1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Potere Health MD: New to the tracker on 1 August 2026. The published line reads From $80/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.